Daria Е. Frolova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daria Е. Frolova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Yu. Torshin
Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
4 shared publications - Olga A. Gromova
Federal Research Center “Informatics and Control” of the Russian Academy of Sciences
3 shared publications - Alexander K. Kostrygin
Ivanovo State Medical University
2 shared publications I. A. Reyer
Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
2 shared publications- Irina Evgenievna Mishina
Saint-Petersburg State University
2 shared publications - Ksenia A. Blinova
Ivanovo State Medical University
2 shared publications
Latest Publications
- 7 April 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Breast cancer in young women: current data on epidemiology, clinical features and personalised approaches to treatment and prevention
Objectives : to conduct a systematic review of current data on breast cancer epidemiology and risk factors; to develop a clinical profle of young breast cancer patients and describe approaches to their treatment and rehabilitation; to develop a prevention strategy for high-risk groups. Material and Methods . A search was conducted in the Web of Science, PubMed, Scopus, and Google Scholar databases. The review incorporated 60 sources (systematic reviews, meta-analyses, randomized clinical trials). A comparative analysis of risk factors, clinical presentation, diagnosis, treatment, and rehabilitation of young breast cancer patients compared to elderly patients was conducted. Results . Breast cancer poses a signifcant health challenge for women aged under 40 years, representing the second leading cause of cancer-related mortality in this age group worldwide. A trend towards an increase in breast cancer incidence is observed among young women. The lack of tailored breast cancer screening for young women causes signifcant diagnostic delays, leading to late-stage cancer at detection, negatively impacting clinical outcomes and increasing the risk of treatmentrelated complications compared to elderly patients. Pathomorphology of tumors detected in young women is characterized by poorly differentiated cells, increased Ki67 expression, the presence of gene mutations, and a predominance of HER2-positive and triple-negative immunohistochemical subtypes. Despite these evident differences, research on breast cancer in young women remains insuffcient, creating gaps in understanding its risk factors, diagnosis, prognosis, and treatment. A lack of age-specifc clinical data and outcomes hinders the adaptation of standard treatment approaches, developed for elderly patients, to the needs of young women. Conclusion . Further research is needed to collect age-specifc clinical data and develop novel treatment strategies for breast cancer in young women, ultimately improving treatment outcomes and identifying promising research directions in this area.
- 7 April 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Breast cancer in young women: current data on epidemiology, clinical features and personalised approaches to treatment and prevention
Objectives : to conduct a systematic review of current data on breast cancer epidemiology and risk factors; to develop a clinical profle of young breast cancer patients and describe approaches to their treatment and rehabilitation; to develop a prevention strategy for high-risk groups. Material and Methods . A search was conducted in the Web of Science, PubMed, Scopus, and Google Scholar databases. The review incorporated 60 sources (systematic reviews, meta-analyses, randomized clinical trials). A comparative analysis of risk factors, clinical presentation, diagnosis, treatment, and rehabilitation of young breast cancer patients compared to elderly patients was conducted. Results . Breast cancer poses a signifcant health challenge for women aged under 40 years, representing the second leading cause of cancer-related mortality in this age group worldwide. A trend towards an increase in breast cancer incidence is observed among young women. The lack of tailored breast cancer screening for young women causes signifcant diagnostic delays, leading to late-stage cancer at detection, negatively impacting clinical outcomes and increasing the risk of treatmentrelated complications compared to elderly patients. Pathomorphology of tumors detected in young women is characterized by poorly differentiated cells, increased Ki67 expression, the presence of gene mutations, and a predominance of HER2-positive and triple-negative immunohistochemical subtypes. Despite these evident differences, research on breast cancer in young women remains insuffcient, creating gaps in understanding its risk factors, diagnosis, prognosis, and treatment. A lack of age-specifc clinical data and outcomes hinders the adaptation of standard treatment approaches, developed for elderly patients, to the needs of young women. Conclusion . Further research is needed to collect age-specifc clinical data and develop novel treatment strategies for breast cancer in young women, ultimately improving treatment outcomes and identifying promising research directions in this area.
- Open Access
- 1 October 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (4) , 112-121
Current concepts of sentinel lymph node biopsy in breast cancer: a literature review
Objective: to systematically analyze the data available in the modern literature on sentinel lymph node biopsy in breast cancer in various clinical situations. Material and Methods. The search was conducted in the Web of science, PubMed, scopus, Google scholar databases. A total of 213 sources devoted to sentinel lymph node biopsy in breast cancer were analyzed, of which 48 were included in the review. Results. Sentinel lymph node biopsy has been established as a standard procedure in early stages of breast cancer, demonstrating efficacy and safety in small tumors, intact lymph nodes and micrometastases. Currently, there is a clear trend toward expanding sentinel lymph node biopsy indications into more complex cases, including changes in lymph node status after neoadjuvant chemotherapy, multicentric cancer, and recurrent breast cancer. Studies are underway to evaluate the safety of sentinel lymph node biopsy during pregnancy, opening up new perspectives for the treatment of this vulnerable group of patients. Expanding the indications for sentinel lymph node biopsy will help avoid radical lymphadenectomy and its associated complications, such as postmastectomy syndrome. this, in turn, will significantly improve the quality of life of cancer patients by reducing postoperative morbidity and accelerating rehabilitation. Conclusion. Further study and implementation of expanded indications for sentinel lymph node biopsy is a promising direction in modern oncology aimed at optimizing treatment and maintaining the quality of life of patients.
- 1 October 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (4) , 112-121
Open AccessCurrent concepts of sentinel lymph node biopsy in breast cancer: a literature review
Objective: to systematically analyze the data available in the modern literature on sentinel lymph node biopsy in breast cancer in various clinical situations. Material and Methods. The search was conducted in the Web of science, PubMed, scopus, Google scholar databases. A total of 213 sources devoted to sentinel lymph node biopsy in breast cancer were analyzed, of which 48 were included in the review. Results. Sentinel lymph node biopsy has been established as a standard procedure in early stages of breast cancer, demonstrating efficacy and safety in small tumors, intact lymph nodes and micrometastases. Currently, there is a clear trend toward expanding sentinel lymph node biopsy indications into more complex cases, including changes in lymph node status after neoadjuvant chemotherapy, multicentric cancer, and recurrent breast cancer. Studies are underway to evaluate the safety of sentinel lymph node biopsy during pregnancy, opening up new perspectives for the treatment of this vulnerable group of patients. Expanding the indications for sentinel lymph node biopsy will help avoid radical lymphadenectomy and its associated complications, such as postmastectomy syndrome. this, in turn, will significantly improve the quality of life of cancer patients by reducing postoperative morbidity and accelerating rehabilitation. Conclusion. Further study and implementation of expanded indications for sentinel lymph node biopsy is a promising direction in modern oncology aimed at optimizing treatment and maintaining the quality of life of patients.
- Open Access
- 3 May 2024
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (1) , 95-105
Chemoreactome screening of aquacobalamin and heptamethyl ester of cyanoaquacobyrinic acid cytotoxic effects on tumor cells with experimental confirmation on BT-474 and A549 cell
Background. The search for an effective and safe pharmacotherapy for tumor diseases includes the evaluation of the action of candidate molecules on various types of tumor cells. Vitamin B12 and its derivatives are promising molecules whose properties can be controlled through chemical modifications.Objective: conducting in silico chemoreactom screening and in vitro experimental study of aquacobalamin and heptamethyl ester of cyanoaquacobyrinic acid (HECСA).Material and methods. Chemoreactome screening was carried out on the basis of a problem-oriented theory of chemograph isomorphism analysis, which is an extension of the algebraic approach to machine learning and recognition problems. Trainable algorithms for calculating chemical distances between molecules were used, on the basis of which the values of half-maximal inhibitory concentration (IC50) were calculated. Screening was carried out for 470 cultures of human tumor cells, including SNB19 (astrocytoma), HCT116 (colon cancer), HeLa (cervical carcinoma), BT-474 (breast duct carcinoma), and A549 (lung carcinoma) cell lines. Dicyanocobyric acid heptamethyl ester ((CN)2Cby(OCH3)7) was obtained by boiling a solution of vitamin B12 in methanol with sulfuric acid (1.0 M) for 4 days. HECСA ((CN)(H2O)Cby(OCH3)7) was obtained by vacuum drying an aqueous solution of (CN)2Cby(OCH3)7 (pH 4.0 and 25 °С). The ester structure and purity were confirmed by 1H nuclear magnetic resonance data, elemental analysis, and MALDI-ToF (matrix-assisted laser desorption/ionization time of flight) mass spectroscopy. Experimental studies of tumor cell cultures were carried out using the MTT testwith aquacobalamin and HECСA on cell lines of immortalized (telomerized) fibroblasts (Fb-hTERT), lung carcinoma (A549), and breast duct cancer (BT-474).Results. Chemoreactome screening of the effects of molecules on tumor cells made it possible to obtain estimates of cell growth IC50 for 470 tumor cell lines. Depending on cell line and vitamin B12 derivative molecule, IC50 values varied in a fairly wide range: from 15 to 2000 nM. In vitro studies on cultures of two human tumor cell lines (BT-474 and A549) and telomerized Fb-hTERT fibroblasts confirmed the cytotoxic effect of aquacobalamin and its hydrophobic derivative HECСA. It was shown that aquacobalamin had weak cytotoxic properties in the concentration range of 3.125–200 µg/l (IC50 > 200 nM), and HECСA significantly reduces the survival of BT-474 and A549 tumor cell lines at high concentrations (100–200 µg/l, IC50 about 100 nM).Conclusion. Correspondence was shown between the results of in silico chemoreactome screening and in vitro cell culture studies: IC50 values for HECСA were significantly lower than for aquacobalamin, and the conversion factor from chemoreactome estimates to experimental ones was almost the same (2.64 for BT-474, and 2.63 for A549). The results of chemoreactome screening for other tumor cell lines can be used to plan further cell experiments with vitamin B12 derivatives.
- 3 May 2024
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (1) , 95-105
Open AccessChemoreactome screening of aquacobalamin and heptamethyl ester of cyanoaquacobyrinic acid cytotoxic effects on tumor cells with experimental confirmation on BT-474 and A549 cell
Background. The search for an effective and safe pharmacotherapy for tumor diseases includes the evaluation of the action of candidate molecules on various types of tumor cells. Vitamin B12 and its derivatives are promising molecules whose properties can be controlled through chemical modifications.Objective: conducting in silico chemoreactom screening and in vitro experimental study of aquacobalamin and heptamethyl ester of cyanoaquacobyrinic acid (HECСA).Material and methods. Chemoreactome screening was carried out on the basis of a problem-oriented theory of chemograph isomorphism analysis, which is an extension of the algebraic approach to machine learning and recognition problems. Trainable algorithms for calculating chemical distances between molecules were used, on the basis of which the values of half-maximal inhibitory concentration (IC50) were calculated. Screening was carried out for 470 cultures of human tumor cells, including SNB19 (astrocytoma), HCT116 (colon cancer), HeLa (cervical carcinoma), BT-474 (breast duct carcinoma), and A549 (lung carcinoma) cell lines. Dicyanocobyric acid heptamethyl ester ((CN)2Cby(OCH3)7) was obtained by boiling a solution of vitamin B12 in methanol with sulfuric acid (1.0 M) for 4 days. HECСA ((CN)(H2O)Cby(OCH3)7) was obtained by vacuum drying an aqueous solution of (CN)2Cby(OCH3)7 (pH 4.0 and 25 °С). The ester structure and purity were confirmed by 1H nuclear magnetic resonance data, elemental analysis, and MALDI-ToF (matrix-assisted laser desorption/ionization time of flight) mass spectroscopy. Experimental studies of tumor cell cultures were carried out using the MTT testwith aquacobalamin and HECСA on cell lines of immortalized (telomerized) fibroblasts (Fb-hTERT), lung carcinoma (A549), and breast duct cancer (BT-474).Results. Chemoreactome screening of the effects of molecules on tumor cells made it possible to obtain estimates of cell growth IC50 for 470 tumor cell lines. Depending on cell line and vitamin B12 derivative molecule, IC50 values varied in a fairly wide range: from 15 to 2000 nM. In vitro studies on cultures of two human tumor cell lines (BT-474 and A549) and telomerized Fb-hTERT fibroblasts confirmed the cytotoxic effect of aquacobalamin and its hydrophobic derivative HECСA. It was shown that aquacobalamin had weak cytotoxic properties in the concentration range of 3.125–200 µg/l (IC50 > 200 nM), and HECСA significantly reduces the survival of BT-474 and A549 tumor cell lines at high concentrations (100–200 µg/l, IC50 about 100 nM).Conclusion. Correspondence was shown between the results of in silico chemoreactome screening and in vitro cell culture studies: IC50 values for HECСA were significantly lower than for aquacobalamin, and the conversion factor from chemoreactome estimates to experimental ones was almost the same (2.64 for BT-474, and 2.63 for A549). The results of chemoreactome screening for other tumor cell lines can be used to plan further cell experiments with vitamin B12 derivatives.
- Open Access
- 16 April 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (3) , 266-272
Study of antitumor effects of human placenta hydrolysate on PC-3, OAW-42, BT-474 cell cultures
Aim. To investigate the antitumor effects of human placenta hydrolysate (HPH) peptides on three hormone-dependent human cell lines: prostate adenocarcinoma, breast carcinoma, and ovarian cancer by metabolic analysis of cell cultures. Materials and methods. The effect of HPH on tumor and control tumor cell lines was evaluated. Study stages: (A) de novo peptide sequencing by collision-induced dissociation mass spectrometry; (B) detection of peptides with anti-tumor properties; (C) expert analysis of the obtained lists of peptides. Results. Dose-dependent cytotoxic effects of HPH on three tumor cell lines are shown: PC-3 (human prostate adenocarcinomas), OAW-42 (human ovarian cancer), BT-474 (human breast carcinomas), and IC50 constants (1.3–2.8 mg/ml) were obtained. The analysis of the HPH peptide fraction showed more than 70 peptides with antitumor properties in the composition of this HPH, including kinase inhibitors: mitogen-activated protein kinases, kappa-bi nuclear factor inhibitor kinase, AKT serine/threonine kinase 1, protein kinase C zeta, interleukin-1 receptor-associated kinase 4 and cyclin-dependent kinase 1. Conclusion. The results of the study indicate not only the oncological safety of the HPH used in therapy but also the mild antitumor effects of this HPH at high concentrations.
- 16 April 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (3) , 266-272
Open AccessStudy of antitumor effects of human placenta hydrolysate on PC-3, OAW-42, BT-474 cell cultures
Aim. To investigate the antitumor effects of human placenta hydrolysate (HPH) peptides on three hormone-dependent human cell lines: prostate adenocarcinoma, breast carcinoma, and ovarian cancer by metabolic analysis of cell cultures. Materials and methods. The effect of HPH on tumor and control tumor cell lines was evaluated. Study stages: (A) de novo peptide sequencing by collision-induced dissociation mass spectrometry; (B) detection of peptides with anti-tumor properties; (C) expert analysis of the obtained lists of peptides. Results. Dose-dependent cytotoxic effects of HPH on three tumor cell lines are shown: PC-3 (human prostate adenocarcinomas), OAW-42 (human ovarian cancer), BT-474 (human breast carcinomas), and IC50 constants (1.3–2.8 mg/ml) were obtained. The analysis of the HPH peptide fraction showed more than 70 peptides with antitumor properties in the composition of this HPH, including kinase inhibitors: mitogen-activated protein kinases, kappa-bi nuclear factor inhibitor kinase, AKT serine/threonine kinase 1, protein kinase C zeta, interleukin-1 receptor-associated kinase 4 and cyclin-dependent kinase 1. Conclusion. The results of the study indicate not only the oncological safety of the HPH used in therapy but also the mild antitumor effects of this HPH at high concentrations.
- Open Access
- 2 April 2024
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (3) , 580-590
Antitumor effects of vitamin B12 in vitro, in vivo, in silico
Objective: to investigate the antitumor effects of various forms of vitamin B12 in combination with various synergistic vitamins and evaluate the prospects for clinical applications. Material and methods. Cell lines BT-474 (breast ductal carcinoma) and A549 (lung carcinoma) were used as an in vitro cell model, and transplantable epidermoid Lewis lung carcinoma (LLC) was used as an in vivo animal tumor model. Animal studies of LLC were carried out on 25 male F 1 hybrid mice (age 2.5–3 months, body weight 23–26 g). In silico research was conducted as a systematic computer analysis of 9,326 scientific sources. Results. In vitro studies on cultures of two human tumor cell lines (BT-474 and A549) confirmed the cytotoxic effect of vitamin B12 (aquacobalamin). It has been shown that vitamin B12 has weak cytotoxic properties in the concentration range of 3.125–200 μg/L (IC50>200 nM), and its hydrophobic derivative (heptamethyl cyanoquacobyric acid ester) significantly reduces the survival of tumor lines. BT-474 and A549 cells at high concentrations (100–200 µg/l, IC50~100 nM). Experimental animals with an in vivo LLС model easily tolerated a drug based on vitamin B12. Exposure to the drug up to the 21 st day of LLС development was accompanied by an increasing tendency to inhibit tumor growth by 10–20% (р=0.059). The results of a systematic in silico review of the literature show that clinical data confirmed the significant antitumor effect of vitamin B12. Conclusion. The cellular model indicated the antitumor properties of vitamin B12 and its hydrophobic derivative. With subchronic intragastric administration of B12 to tumor-bearing animals, a steady tendency to inhibit the LLС growth was observed. Analysis of clinical data confirmed the feasibility of the antitumor use of vitamin B12 individually and in combination with synergistic vitamins.
- 2 April 2024
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (3) , 580-590
Open AccessAntitumor effects of vitamin B12 in vitro, in vivo, in silico
Objective: to investigate the antitumor effects of various forms of vitamin B12 in combination with various synergistic vitamins and evaluate the prospects for clinical applications. Material and methods. Cell lines BT-474 (breast ductal carcinoma) and A549 (lung carcinoma) were used as an in vitro cell model, and transplantable epidermoid Lewis lung carcinoma (LLC) was used as an in vivo animal tumor model. Animal studies of LLC were carried out on 25 male F 1 hybrid mice (age 2.5–3 months, body weight 23–26 g). In silico research was conducted as a systematic computer analysis of 9,326 scientific sources. Results. In vitro studies on cultures of two human tumor cell lines (BT-474 and A549) confirmed the cytotoxic effect of vitamin B12 (aquacobalamin). It has been shown that vitamin B12 has weak cytotoxic properties in the concentration range of 3.125–200 μg/L (IC50>200 nM), and its hydrophobic derivative (heptamethyl cyanoquacobyric acid ester) significantly reduces the survival of tumor lines. BT-474 and A549 cells at high concentrations (100–200 µg/l, IC50~100 nM). Experimental animals with an in vivo LLС model easily tolerated a drug based on vitamin B12. Exposure to the drug up to the 21 st day of LLС development was accompanied by an increasing tendency to inhibit tumor growth by 10–20% (р=0.059). The results of a systematic in silico review of the literature show that clinical data confirmed the significant antitumor effect of vitamin B12. Conclusion. The cellular model indicated the antitumor properties of vitamin B12 and its hydrophobic derivative. With subchronic intragastric administration of B12 to tumor-bearing animals, a steady tendency to inhibit the LLС growth was observed. Analysis of clinical data confirmed the feasibility of the antitumor use of vitamin B12 individually and in combination with synergistic vitamins.
- Open Access
- 17 April 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 152-158
About antiviral effects of vitamin D
Preventing infectious diseases is very important in obstetric and gynaecological practice. Vitamin D is a complex regulator of innate and adaptive immunity. It is known that lack of vitamin D reduces antibacterial and antiviral immunity, stimulates the development of pathologies associated with chronic systemic inflammation. Evidence from evidence-based medicine indicates the importance of using vitamin D preparations to support immunity. The results of fundamental and clinical studies have shown that chronic inflammation and congenital immunity disorders resulting from vitamin D deficiency significantly reduce the body’s resistance not only to tuberculosis, but also to viral hepatitis, acute respiratory infections, papillomavirus and herpesvirus. In addition to a pronounced antibacterial effect, vitamin D is also characterized by its antiviral action. By increasing the expression of interferon-alpha, cathecidine, defensin and antiviral microRNA, vitamin D activates various mechanisms of congenital antiviral immunity. Studies show the need to compensate for vitamin D deficiency for successful therapy of viral hepatitis, respiratory infections, human papillomavirus (HPV) and herpesvirus. In the present article the molecular fundamentals of antiviral action of vitamin D are sequentially considered, as well as the results of fundamental and clinical studies indicating the action of vitamin D against the viruses of hepatitis, herpes, RSV, Epstein-Barr, human papillomavirus, the possibility of using vitamin D in the treatment of these and other viral pathologies is considered. The authors analyzed data on the effect of vitamin D on immunity functions and antiviral protection of the human body.
- 17 April 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 152-158
Open AccessAbout antiviral effects of vitamin D
Preventing infectious diseases is very important in obstetric and gynaecological practice. Vitamin D is a complex regulator of innate and adaptive immunity. It is known that lack of vitamin D reduces antibacterial and antiviral immunity, stimulates the development of pathologies associated with chronic systemic inflammation. Evidence from evidence-based medicine indicates the importance of using vitamin D preparations to support immunity. The results of fundamental and clinical studies have shown that chronic inflammation and congenital immunity disorders resulting from vitamin D deficiency significantly reduce the body’s resistance not only to tuberculosis, but also to viral hepatitis, acute respiratory infections, papillomavirus and herpesvirus. In addition to a pronounced antibacterial effect, vitamin D is also characterized by its antiviral action. By increasing the expression of interferon-alpha, cathecidine, defensin and antiviral microRNA, vitamin D activates various mechanisms of congenital antiviral immunity. Studies show the need to compensate for vitamin D deficiency for successful therapy of viral hepatitis, respiratory infections, human papillomavirus (HPV) and herpesvirus. In the present article the molecular fundamentals of antiviral action of vitamin D are sequentially considered, as well as the results of fundamental and clinical studies indicating the action of vitamin D against the viruses of hepatitis, herpes, RSV, Epstein-Barr, human papillomavirus, the possibility of using vitamin D in the treatment of these and other viral pathologies is considered. The authors analyzed data on the effect of vitamin D on immunity functions and antiviral protection of the human body.